Flaws Of ‘Virtual’ Advisory Committees Highlighted At Aducanumab Panel

The intensely negative advisory committee for Biogen’s proposed Alzheimer’s therapy was a shocker. Would it have happened if US FDA had been able to convene an in-person event instead of a ‘virtual’ one?

Is it easier to give an application the thumbs down over Adobe Connect? • Source: Shutterstock

Center for Drug Evaluation & Research Deputy Director for Clinical Science Robert Temple has not yet participated in a “virtual” advisory committee meeting hosted by the US Food & Drug Administration, but he is concerned about the impact of the format.

“As a general matter, it matters when people are in the room,” Temple said during a Prevision Policy/Friends of Cancer Research event recorded on 20 October. “They look at each...

More from US FDA Performance Tracker

More from Regulatory Trackers